Merck & Co Makes Case For Molnupiravir After Narrow FDA Nod
Backing Comes Day After Pfizer's Paxlovid Green Light
US regulators have granted emergency authorization to the antiviral molnupiravir but only for use when "alternative COVID-19 treatment options authorized by the FDA are not accessible or clinically appropriate."
